Mikkelsen T S, Toft P
Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
Acta Anaesthesiol Scand. 2005 Jul;49(6):859-64. doi: 10.1111/j.1399-6576.2005.00577.x.
(I) To investigate the kinetics of the myoglobin and creatine kinase (CK) in rhabdomyolysis. Especially to describe those patients in whom an isolated increase in the myoglobin or the CK occurred at a later stage. (II) To evaluate the sensitivity of the myoglobin and the CK as prognostic tools for the development of Acute renal failure (ARF). (III) To investigate the effect of continuous venovenous haemodiafiltration (CVVHDF) on the myoglobin elimination in ARF.
Prospective and retrospective cohort study carried out in an ICU of a university hospital. A total of 47 critically ill patients with rhabdomyolysis and a plasma myoglobin > 5000 microg l(-1) were admitted between July 1998 and July 2003.
(I) The myoglobin peaked 0.66 +/- 0.6 days before the CK. The elimination kinetics of the myoglobin was faster than for the CK. (II) Fifty percent developed ARF. Mortality in the ARF patients was 52% compared to 14% in the non-ARF patients. The sensitivity and specificity of developing ARF were higher with the myoglobin in comparison to the CK. (III) In non-ARF, t(1/2) CK was 25.5 h and t(1/2) myoglobin was 17 h (13-23). In those with ARF treated with CVVHDF, t(1/2) CK was 24.8 and t(1/2) myoglobin was 21 h (17-29).
(I) The myoglobin peaked earlier than the CK. (II) The myoglobin was a better prognostic tool than the CK. However, the myoglobin also has a wide interindividual range. (III) Though the myoglobin is eliminated in ultrafiltration t(1/2) myoglobin, it was not faster in patients with ARF treated with CVVHDF compared to non-ARF patients.
(I)研究横纹肌溶解症中肌红蛋白和肌酸激酶(CK)的动力学。尤其要描述那些在后期出现肌红蛋白或CK单独升高的患者。(II)评估肌红蛋白和CK作为急性肾衰竭(ARF)发生的预后工具的敏感性。(III)研究持续静静脉血液透析滤过(CVVHDF)对ARF中肌红蛋白清除的影响。
在一家大学医院的重症监护病房进行前瞻性和回顾性队列研究。1998年7月至2003年7月期间,共收治了47例横纹肌溶解症且血浆肌红蛋白>5000μg l⁻¹的重症患者。
(I)肌红蛋白峰值比CK提前0.66±0.6天出现。肌红蛋白的清除动力学比CK更快。(II)50%的患者发生了ARF。ARF患者的死亡率为52%,而非ARF患者为14%。与CK相比,肌红蛋白预测ARF发生的敏感性和特异性更高。(III)在未发生ARF的患者中,CK的半衰期为25.5小时,肌红蛋白的半衰期为17小时(13 - 23小时)。在接受CVVHDF治疗的ARF患者中,CK的半衰期为24.8小时,肌红蛋白的半衰期为21小时(17 - 29小时)。
(I)肌红蛋白峰值早于CK。(II)肌红蛋白是比CK更好的预后工具。然而,肌红蛋白的个体差异范围也很大。(III)尽管肌红蛋白可在超滤中被清除(半衰期),但接受CVVHDF治疗的ARF患者的肌红蛋白清除速度并不比未发生ARF的患者更快。